References
- Genis D, Marquez F, Corral J, Volpini V. Ataxia and hyperthermia. Mov. Disord.21(Suppl. 15), P12 S332 (2006).
- Jog M, Khandekar N, Attar A. Tolerability of tetrabenazine in Huntington’s disease. Mov. Disord.21(Suppl. 15), P106 S357 (2006).
- Meyniel C, Xie J, Witjas T et al. Pallidal DBS is effective in improving all types of dyskinesias induced by neuroleptics. Mov. Disord.21(Suppl. 15), P168 S374 (2006).
- Bhidayasiri R, Srikijvilaikul T, Lerdlum S, Tuchinda L, Phanthumchinda K, Kaoroptham S. Significant improvement following bilateral pallidal stimulation in neuroleptic-induced tardive dyskinesia. Mov. Disord.21(Suppl. 15), P161 S372 (2006).
- Schneider SA, Aggarwal A, Bhatt M et al. Severe tongue protrusion dystonia: clinical syndromes and their management. Mov. Disord.21(Suppl. 15), P244 S396 (2006).
- Winkelman JM, Sethi KD, Kushida CA, Becker PM. Pramipexole improves a broad range of facets of restless legs syndrome. Mov. Disord.21(Suppl. 15), P374 S430 (2006).
- Geyer J, Earl N, Tolsen J. Ropinirole reduces severity of restless legs syndromes (RLS) in patients with symptom onset in the late afternoon/early evening. Mov. Disord.21(Suppl. 15), P386 S433 (2006).
- Geisler P, Trenkwalder C, Schollmayer E, Oertal WH. Rotigotine transdermal patch improves daytime symptoms and activities of daily living in restless legs syndrome patients. Mov. Disord.21(Suppl. 15), P397 S436 (2006).
- Peckham EL, Slagle E, Tzatha E et al. Sensorimotor integration is abnormal in primary restless legs syndrome. Mov. Disord.21(Suppl. 15), P155 S370 (2006).
- Hatano T, Kubo S, Funayama M et al. LRRK2 binds cellular membranes. Mov. Disord.21(Suppl. 15), P982 S599 (2006).
- Muzerengi S, Bharkhada A, Forbes A, Williams A, Ray Chaudhuri K. Daytime sleepiness in untreated and treated Parkinson’s disease. Mov. Disord.21(Suppl. 15), P954 S591 (2006).
- Cheon S, Lee MS, Yang CK, Park MJ, Kim JW. Sleep disturbances in patient with Parkinson’s disease: polysomnography findings. Mov. Disord.21(Suppl. 15), P600 S491 (2006).
- Devos D, Krystkowiak P, Dujardin K et al. Improvement of gait by chronic high doses of methylphenidate in advanced parkinsonian patients under deep brain stimulation. Mov. Disord.21(Suppl. 15), P1018 S609 (2006).
- Naidu Y, Schapira AHV, Martinez-Martin P et al. International validation of the first comprehensive unified non-motor symptoms scale (NMSS) for Parkinson’s disease (PD). Mov. Disord.21(Suppl. 15), P1031 S613 (2006).
- Ross W, Abbott RD, Petrovitch H, Davis DG, Tanner CM, White LR. Bowel movement frequency and incidental Lewy bodies. Mov. Disord.21(Suppl. 15), P1196 S659 (2006).
- Ascherio A, LeWitt PA, Watts A et al. CSF as well as serum urate are predictors of Parkinson’s disease progression. Mov. Disord.21(Suppl. 15), LB2 (2006).